Tanshinone IIA nanostructure lipid carrier, preparation method and application thereof, and tanshinone IIA nanostructure lipid carrier freeze-dried powder and application thereof

By preparing tanshinone ⅡA nanostructured lipid carriers, using the composite technology and emulsifiers of solid and liquid lipids, the problem of tanshinone ⅡA being difficult to dissolve in water is solved, its stability and compliance are improved, and effective drug encapsulation is achieved and sustained release effect.

CN118903155APending Publication Date: 2024-11-08HANGZHOU NORMAL UNIVERSITY
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411259710.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-10
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Tanshinone IIA is insoluble in water and has limited its clinical application. The market's sodium sulfonate injection has poor stability and low patient compliance.

Method used

Tanshinone IIA nanostructured lipid carrier was prepared by combining solid lipids with liquid lipids, combined with emulsifier and water, and a nanostructured lipid carrier with a particle size of less than 135nm and an encapsulation rate of more than 85%. And a stable carrier powder is obtained by lyophilization, which improves the load content and water solubility of the drug.

Benefits of technology

It improves the stability and patient compliance of tanshinone IIA, achieves effective encapsulation and sustained release of drugs, and has higher control of drug release and targeting effects, and has higher stability than traditional microparticle drug delivery systems.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903155A_ABST
    Figure CN118903155A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of drug carriers, and particularly relates to a tanshinone IIA nanostructure lipid carrier and a preparation method and application thereof, and tanshinone IIA nanostructure lipid carrier freeze-dried powder and application thereof. According to the tanshinone IIA nanostructure lipid carrier disclosed by the invention, solid lipid and liquid lipid are compounded for use, so that a very good synergistic effect is achieved, the drug encapsulation efficiency can effectively reach 85% or above, and the corresponding dispersity and the carrier particle size can reach a relatively good level. The tanshinone IIA is embedded by using a nanostructure lipid carrier technology, so that the loading content of the tanshinone IIA is increased, and the water solubility of the tanshinone IIA can be improved. The tanshinone IIA nanostructure lipid carrier provided by the invention not only has the effects of controlling drug release, targeting and the like, but also has higher stability compared with particle drug delivery systems such as lipidosome, microspheres and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of drug carriers, and specifically relates to a tanshinone ⅡA nanostructured lipid carrier and a preparation method and application thereof, and a tanshinone ⅡA nanostructured lipid carrier freeze-dried powder and an application thereof. Background Art

[0002] Danshen is the dried root and rhizome of the plant Salvia miltiorrhiza of the Lamiaceae family. Tanshinone IIA (TSNⅡA) is the main fat-soluble component in Danshen and has a wide range of pharmacological effects: 1. Anti-tumor effect. It has a significant inhibitory effect on tumors of the digestive system, reproductive system, and urinary system. 2. Anti-cardiovascular and cerebrovascular disease effect. Tanshinone IIA can inhibit thrombosis, protect the myocardium, and protect vascular endothelial cells. 3. Anti-inflammatory effect. Tanshinone IIA can inhibit the action of cytokines, and more and more researchers have found that TSNⅡA has a significant effect on chronic obstructive pulmonary disease (COPD). Due to its wide range of pharmacological effects, more and more researchers have paid attention to and started to study Tanshinone IIA, but its physical and chemical properties of poor solubility in water limit its clinical application. Studies have shown that sulfonation of Tanshinone IIA can enhance its solubility, and TSNⅡA sodium sulfonate injection has appeared on the market, but its polarity is large, and the injection itself has poor stability and low patient compliance. Summary of the invention

[0003] The purpose of the present invention is to provide a tanshinone ⅡA nanostructured lipid carrier and a preparation method and application thereof, a tanshinone ⅡA nanostructured lipid carrier freeze-dried powder and an application thereof. The tanshinone ⅡA nanostructured lipid carrier provided by the present invention has higher stability and patient compliance.

[0004] In order to achieve the above object, the present invention provides the following technical solutions:

[0005] The present invention provides a tanshinone ⅡA nanostructured lipid carrier, the preparation raw materials of which include tanshinone ⅡA, composite lipid, emulsifier and water;

[0006] The complex lipids include solid lipids and liquid lipids.

[0007] Preferably, the solid lipid comprises one or more of polyethylene glycol 100 stearate, glyceryl monostearate, glyceryl behenate, glyceryl laurate, glyceryl myristicate and stearic acid; the liquid lipid comprises one or more of tricaprylin, liquid paraffin, castor oil, peppermint oil and oleic acid;

[0008] The emulsifier includes one or more of Poloxamer 188, Tween 20, Tween 40, Tween 60, Tween 80, Span 20, Span 40, Span 60, Span 80, Bian Ze 35 and sodium lauryl sulfate.

[0009] Preferably, the mass ratio of the solid lipid to the liquid lipid is 1.25-2.0:1;

[0010] The mass ratio of the composite lipid to the emulsifier is 2.4-3.6:0.05-0.3;

[0011] The mass ratio of tanshinone ⅡA to the composite lipid is 0.01-0.02:1.2-3.6;

[0012] The mass ratio of tanshinone ⅡA to water is 0.01-0.02:50.

[0013] Preferably, the particle size of the tanshinone ⅡA nanostructured lipid carrier is less than 135 nm;

[0014] The encapsulation rate of the tanshinone ⅡA nanostructured lipid carrier is above 85%.

[0015] The present invention also provides a method for preparing the tanshinone ⅡA nanostructured lipid carrier described in the above technical solution, comprising the following steps:

[0016] The tanshinone ⅡA, the solid lipid and the liquid lipid are first heated and mixed to obtain an oil phase;

[0017] The emulsifier and water are heated and mixed for a second time to obtain a water phase;

[0018] After the oil phase and the water phase are mixed, emulsification and homogenization are performed in sequence to obtain the tanshinone ⅡA nanostructured lipid carrier.

[0019] Preferably, the temperature of the first heating and mixing is 75-85°C; the temperature of the second heating and mixing is 65-80°C.

[0020] Preferably, the emulsification time is 1 to 3 minutes, and the emulsification is carried out under stirring, and the stirring speed is 5000 rpm.

[0021] Preferably, the homogenization pressure is 800-1200 bar, and the homogenization is performed 3-6 times.

[0022] The present invention also provides a tanshinone ⅡA nanostructured lipid carrier freeze-dried powder, which is obtained by freeze-drying the tanshinone ⅡA nanostructured lipid carrier described in the above technical scheme or the tanshinone ⅡA nanostructured lipid carrier prepared by the preparation method described in the above technical scheme.

[0023] The present invention also provides the use of the tanshinone ⅡA nanostructured lipid carrier described in the above technical scheme, the tanshinone ⅡA nanostructured lipid carrier prepared by the preparation method described in the above technical scheme, or the tanshinone ⅡA nanostructured lipid carrier freeze-dried powder described in the above technical scheme in the preparation of anti-tumor drugs, anti-cardiovascular and cerebrovascular disease drugs or anti-inflammatory drugs.

[0024] The present invention provides a tanshinone ⅡA nanostructured lipid carrier, the preparation raw materials include tanshinone ⅡA, composite lipids, emulsifiers and water; the composite lipids include solid lipids and liquid lipids. The tanshinone ⅡA nanostructured lipid carrier of the present invention achieves a good synergistic effect by using solid lipids and liquid lipids in combination, and can effectively make the drug encapsulation rate reach more than 85%, and the corresponding dispersibility and carrier particle size can reach a good level. The present invention uses nanostructured lipid carrier technology to embed tanshinone ⅡA, increase its loading content, and improve its water solubility. The tanshinone ⅡA nanostructured lipid carrier provided by the present invention not only has the functions of controlling drug release and targeting, but also has higher stability compared with microparticle delivery systems such as liposomes and microspheres.

[0025] The present invention also provides a method for preparing the tanshinone ⅡA nanostructured lipid carrier described in the above technical solution, comprising the following steps: first heating and mixing tanshinone ⅡA, solid lipids and liquid lipids to obtain an oil phase; second heating and mixing an emulsifier and water to obtain an aqueous phase; after mixing the oil phase and the aqueous phase, emulsifying and homogenizing in sequence to obtain the tanshinone ⅡA nanostructured lipid carrier. The preparation method provided by the present invention has the advantages of simple process and easy operation, and the process is convenient, controllable and repeatable.

[0026] The present invention also provides a tanshinone ⅡA nanostructured lipid carrier freeze-dried powder, which is obtained by freeze-drying the tanshinone ⅡA nanostructured lipid carrier described in the above technical solution or the tanshinone ⅡA nanostructured lipid carrier prepared by the preparation method described in the above technical solution. The freeze-dried powder provided by the present invention can slowly and continuously release the drug and has a certain sustained release effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 This is a transmission electron microscopy image of the tanshinone ⅡA nanostructured lipid carrier obtained in Example 2;

[0028] Figure 2 This is a physical picture of the freeze-dried powder of the Tanshinone ⅡA nanostructured lipid carrier obtained in Example 2;

[0029] Figure 3 is the standard curve of Tanshinone ⅡA reference solution;

[0030] Figure 4This is the HPLC chart of Tanshinone ⅡA reference substance;

[0031] Figure 5 This is the HPLC chart of the tanshinone ⅡA test sample;

[0032] Figure 6 is the in vitro release curve of Tanshinone ⅡA;

[0033] Figure 7 This is the in vitro release curve of tanshinone ⅡA nanostructured lipid carrier freeze-dried powder. DETAILED DESCRIPTION

[0034] The present invention provides a tanshinone ⅡA nanostructured lipid carrier, the preparation raw materials of which include tanshinone ⅡA, composite lipid, emulsifier and water;

[0035] The complex lipids include solid lipids and liquid lipids.

[0036] In the present invention, unless otherwise specified, all components are commercially available products well known to those skilled in the art.

[0037] In the present invention, the solid lipid preferably includes one or more of polyethylene glycol 100 stearate, glyceryl monostearate, glyceryl behenate, glyceryl laurate, glyceryl myristic acid and stearic acid; the liquid lipid preferably includes one or more of tricaprylin, liquid paraffin, castor oil, peppermint oil and oleic acid; the emulsifier preferably includes one or more of poloxamer 188, Tween 20, Tween 40, Tween 60, Tween 80, Span 20, Span 40, Span 60, Span 80, Bian Ze 35 and sodium lauryl sulfate.

[0038] In the present invention, the mass ratio of the solid lipid to the liquid lipid is preferably 1.25-2.0:1. In the present invention, the mass ratio of the complex lipid to the emulsifier is preferably 2.4-3.6:0.05-0.3. In the present invention, the mass ratio of tanshinone ⅡA to the complex lipid is preferably 0.01-0.02:1.2-3.6. In the present invention, the mass ratio of tanshinone ⅡA to water is preferably 0.01-0.02:50.

[0039] In the present invention, the particle size of the tanshinone ⅡA nanostructured lipid carrier is preferably less than 135 nm; the encapsulation rate of the tanshinone ⅡA nanostructured lipid carrier is preferably more than 85%.

[0040] The present invention also provides a method for preparing the tanshinone ⅡA nanostructured lipid carrier described in the above technical solution, comprising the following steps:

[0041] The tanshinone ⅡA, the solid lipid and the liquid lipid are first heated and mixed to obtain an oil phase;

[0042] The emulsifier and water are heated and mixed for a second time to obtain a water phase;

[0043] After the oil phase and the water phase are mixed, emulsification and homogenization are performed in sequence to obtain the tanshinone ⅡA nanostructured lipid carrier.

[0044] The present invention conducts a first heating and mixing of tanshinone ⅡA, solid lipid and liquid lipid to obtain an oil phase.

[0045] In the present invention, the temperature of the first heating and mixing is preferably 75-85° C. In the present invention, the process of the first heating and mixing is preferably: after the solid lipid and the liquid lipid are heated and dissolved, tanshinone IIA is added to dissolve.

[0046] In the present invention, the emulsifier and water are subjected to a second heating and mixing process to obtain a water phase.

[0047] In the present invention, the water is preferably pure water. In the present invention, the temperature of the second heating and mixing is preferably 65 to 80°C.

[0048] After obtaining the water phase and the oil phase, the present invention mixes the oil phase and the water phase, and then sequentially emulsifies and homogenizes them to obtain the tanshinone ⅡA nanostructured lipid carrier.

[0049] In the present invention, the order of mixing the water phase and the oil phase is preferably: slowly injecting the water phase into the oil phase under stirring. The present invention adopts the method of adding the water phase to the oil phase. Firstly, less water phase remains on the beaker wall, which improves the accuracy of the experiment; secondly, the specific heat capacity of water is large, and the temperature decreases less when injected, thereby ensuring that the temperature of the oil phase and the water phase is consistent during emulsification, and the emulsification is complete.

[0050] In the present invention, the emulsification time is preferably 1 to 3 minutes, more preferably 2 minutes. The emulsification is preferably carried out under stirring, and the stirring speed is preferably 5000 rpm.

[0051] In the present invention, the homogenization pressure is preferably 800 to 1200 bar, and more preferably 1000 bar; the homogenization is performed 3 to 6 times.

[0052] The present invention also provides a lyophilized powder of a tanshinone ⅡA nanostructured lipid carrier, which is obtained by lyophilizing the tanshinone ⅡA nanostructured lipid carrier described in the above technical solution or the tanshinone ⅡA nanostructured lipid carrier prepared by the preparation method described in the above technical solution. The present invention has no special limitation on the lyophilization process, and a method well known to those skilled in the art can be used.

[0053] The present invention also provides the use of the tanshinone ⅡA nanostructured lipid carrier described in the above technical scheme, the tanshinone ⅡA nanostructured lipid carrier prepared by the preparation method described in the above technical scheme, or the tanshinone ⅡA nanostructured lipid carrier freeze-dried powder described in the above technical scheme in the preparation of anti-tumor drugs, anti-cardiovascular and cerebrovascular disease drugs or anti-inflammatory drugs.

[0054] The technical solutions in the present invention will be described clearly and completely below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0055] Examples 1 to 13

[0056] Prepare materials according to Table 1;

[0057] Tricaprylin and polyethylene glycol 100 stearate were mixed, heated to 80°C, and after they were completely melted, tanshinone ⅡA was added to completely dissolve them to obtain an oil phase; poloxamer 188 was completely dissolved in pure water and heated to 80°C as an aqueous phase. Under high-speed stirring, the aqueous phase was slowly injected into the oil phase, and emulsified at a speed of 5000 rpm for 2 minutes to obtain colostrum. The colostrum was homogenized 6 times under high pressure at a homogenization pressure of 1000 bar to obtain a tanshinone ⅡA nanostructured lipid carrier.

[0058] Embodiment 14

[0059] The tanshinone ⅡA nanostructured lipid carrier obtained in Example 2 was freeze-dried to obtain a tanshinone ⅡA nanostructured lipid carrier freeze-dried powder. The actual picture of the obtained freeze-dried powder is as follows: Figure 2 shown.

[0060] Performance Testing

[0061] Test Example 1

[0062] 1. Determination of particle size and Zeta potential

[0063] The tanshinone ⅡA nanostructured carrier was diluted 25 times, placed in a Malvern laser particle size analyzer, and its particle size was measured at 20°C for 3 times, and the middle value was taken. The tanshinone ⅡA nanostructured carrier was diluted 25 times, placed in a Malvern laser particle size analyzer, and its Zeta potential was measured at 20°C for 3 times, and the middle value was taken.

[0064] 2. Determination of encapsulation efficiency

[0065] 2.1 Determination of detection wavelength

[0066] Accurately weigh an appropriate amount of Tanshinone ⅡA reference substance, dissolve it in anhydrous ethanol and dilute to the mark as the reference substance stock solution (1 mg / mL). Take an appropriate amount of the stock solution in a 10 ml volumetric bottle and dilute it with ethanol. Scan it with a UV spectrophotometer within 200-400 nm. The results show that Tanshinone ⅡA has a maximum absorption at a wavelength of 259 nm, and the related excipients have basically no interference here, so 259 nm was selected as the detection wavelength in this experiment.

[0067] 2.2 Establishment of standard curve

[0068] Accurately weigh 0.005g of Tanshinone ⅡA, use anhydrous ethanol as solvent to prepare 100μg / mL Tanshinone ⅡA anhydrous ethanol solution, dilute the prepared Tanshinone ⅡA anhydrous ethanol solution to 2μg / mL, 4μg / mL, 6μg / mL, 8μg / mL, and 10μg / mL respectively. Use an ultraviolet spectrophotometer at a wavelength of 259nm to measure the absorbance, substitute the measured absorbance and concentration into Excel to obtain the standard curve of Tanshinone ⅡA, the standard curve equation is y=0.0864x+0.0481, r=0.9979.

[0069] 2.3 Sample determination

[0070] 1mL of tanshinone ⅡA nanostructured lipid carrier was taken into an EP tube, centrifuged at 4000r / min for 10min at 4℃, the upper suspension was removed, leaving the unencapsulated tanshinone ⅡA raw material, 1mL of anhydrous ethanol was added, dissolved completely, and the ultraviolet absorption was measured at 259nm. The results were substituted into the standard curve to calculate the content, that is, the amount of free drug. Another 1mL of tanshinone ⅡA nanostructured lipid carrier suspension was taken into a round-bottom flask, 2mL of anhydrous ethanol was added, ultrasonically destroyed, anhydrous ethanol and water were removed by rotary evaporation, 5mL of anhydrous ethanol was added, ultrasonically, fully dissolved, and appropriately diluted to make the absorbance between 0.3 and 0.7, and its ultraviolet absorption was measured. The results were substituted into the standard curve to calculate the total amount of drug. The encapsulation rate calculation formula is as follows.

[0071]

[0072] 2.4 Recovery of separation methods

[0073] Prepare a blank nanostructured lipid carrier (i.e., without drug loading), accurately weigh 5 mg of Tanshinone ⅡA, and mix it evenly with 45 mL of blank nanostructured lipid carrier. Centrifuge at 3500r / min for 10 minutes in an ultracentrifuge, remove the supernatant, dissolve the precipitate with an appropriate amount of anhydrous ethanol, and then measure the absorbance. Substitute the absorbance into the standard curve to calculate the concentration of Tanshinone ⅡA. The recovery rate is calculated to be 98.7% through the concentration, which proves that the centrifugation method can be used to determine the encapsulation rate of Tanshinone ⅡA nanostructured lipid carrier.

[0074] The particle size and encapsulation efficiency of the tanshinone ⅡA nanostructured lipid carriers obtained in Examples 1 to 13 were tested, and the test results obtained are shown in Table 1, where the lipid mass is the total mass of the solid lipid and the liquid lipid;

[0075] Table 1 is the ingredient list and test results of Examples 1 to 13

[0076]

[0077]

[0078] Test Example 2

[0079] The suspension of the tanshinone ⅡA nanostructured lipid carrier obtained in Example 2 was dropped onto a copper mesh, allowed to stand for 5 minutes, and then dried with a filter paper. A 2.0% phosphotungstic acid solution was then added to the copper mesh for negative staining for 3 minutes, and the mesh was naturally dried. The mesh was observed and photographed using a transmission electron microscope. The transmission electron microscope image obtained is shown in FIG. Figure 1 As shown. Figure 1 It can be seen that Tanshinone ⅡA is round or quasi-round, with a smooth surface and relatively uniform size and distribution.

[0080] Test Example 3

[0081] The in vitro drug release of the lyophilized powder of the tanshinone ⅡA nanostructured lipid carrier obtained in Example 2 was tested by high performance liquid chromatography, with the tanshinone raw material as a control;

[0082] (1) The test conditions include: the chromatographic conditions selected are Agilent C18 column; the mobile phase is methanol-water solution (72:28), the column temperature is 25°C, the volume flow rate is 1.0 mL / min; the detection wavelength is 270 nm; the injection volume is 20.00 μL;

[0083] (2) Preparation of reference solution: 5 mg of Tanshinone ⅡA was accurately weighed on an analytical balance, placed in a small beaker, and dissolved with 4 mL of anhydrous ethanol accurately measured. Then, it was poured into a 10 mL volumetric flask and placed in an ultrasonic cleaner for 20 min. After complete dissolution, 4 mL of purified water was added, and finally the volume was fixed with 50% ethanol to make a solution with a concentration of 0.5 mg / mL, thus obtaining a 0.5 mg / mL Tanshinone ⅡA reference solution.

[0084] (3) Determination of the limit of quantification: Accurately measure the 0.5 mg / mL Tanshinone ⅡA reference solution obtained above, dilute it 2, 2.5, 5, 10, 20, 25, 50, 100, 200, 500, 1000, 2000 times, and finally prepare a series of solutions with concentrations of 25, 20, 10, 5, 2.5, 2, 1, 0.5, 0.25, 0.1, 0.05, and 0.025 μg / mL. According to the optimal chromatographic conditions of (1), inject the samples from high concentration to low concentration. The signal-to-noise ratio of the 0.025 μg / mL reference solution is 9.7, so the limit of quantification of this product is 0.05 ng.

[0085] (4) Drawing of the standard curve: Accurately measure 0.5 mg / mL of Tanshinone ⅡA reference solution, dilute it by 2, 2.5, 5, 10, 50, and 2000 times respectively, and finally prepare a series of solutions with concentrations of 25, 20, 10, 5, 1, and 0.025 μg / mL. Inject the solutions in sequence according to the optimal chromatographic conditions of (1). The results are shown in Table 2. Then, draw a scatter plot of the above results with the peak area as the ordinate and the concentration as the abscissa, add a trend line, and finally display the public and R square values, which is the required standard curve. The standard curve is y=117.27x-3.9497, R=0.9998, and shows a good linear relationship in the range of 0.025-25 μg / mL (see the standard curve). Figure 3 );

[0086] Table 2 Results of standard curve drawing

[0087] name Dilution multiple Concentration (μg / mL) Retention time Peak area Biaozhun1 2 25 9.683 2943.1 Biaozhun2 2.5 20 9.704 2342.6 Biaozhun3 5 10 9.587 1137.6 Biaozhun4 10 5 9.757 571.3 Bizohuan5 50 1 9.08 120.8 Biaozhun6 2000 0.025 9.897 0

[0088] (5) Preparation of test solution: Accurately weigh the lyophilized powder of the tanshinone ⅡA nanostructured lipid carrier obtained in Example 2, place it in a treated dialysis bag, seal both ends, and place it in a release cup containing 50 mL of release medium (0.5% SDS saline). After 48 hours, sample 2 mL of the solution, filter the sampled 2 mL of the solution through a 0.45 μm microporous filter membrane, and take the filtrate to obtain the test solution.

[0089] (6) Determination of precision and stability:

[0090] Accurately measure 1 mL of 0.5 mg / mL Tanshinone ⅡA reference solution and place it in a 10 mL brown volumetric flask. First, add 8 mL of 50% ethanol to dilute it, and finally make it up to volume with 50% ethanol. Shake it thoroughly and finally make a 10 μg / mL Tanshinone ⅡA solution. Inject it according to the chromatographic conditions of (1), measure the peak area, perform 6 parallel measurements, and calculate the precision. The results are shown in Table 3, and the RSD is 1.62%. The RSD of 1.62% indicates that the precision of the instrument is good.

[0091] Table 3 Precision experiment of Tanshinone ⅡA reference substance

[0092]

[0093]

[0094] Accurately measure 1 mL of 0.5 mg / mL Tanshinone ⅡA reference solution, and operate in the same way as the precision test, and finally dilute it to 10 μg / mL Tanshinone ⅡA solution. According to the chromatographic conditions of (1), the sample is injected at 0.3, 6, 9, 12, and 15 h, and the peak area is measured. The results are shown in Table 4, and the RSD is 0.44%. The RSD of 0.44% indicates that the stability of the instrument is good;

[0095] Table 4 Stability test of Tanshinone ⅡA reference substance

[0096]

[0097] (7) Repeatability study: Weigh 5 mg of Tanshinone ⅡA accurately and prepare a solution with a concentration of 0.5 mg / mL according to the method for preparing the reference solution. Repeat the same method 6 times to prepare different solutions. Then, according to the chromatographic conditions of (1), inject the sample 6 times and measure the peak area. The results are shown in Table 5, and the RSD is 2.01%. The RSD of 2.01% indicates that the repeatability of this experiment is good.

[0098] Table 5 Repeatability test of Tanshinone ⅡA reference substance

[0099]

[0100] (8) Method specificity experiment

[0101] Take Tanshinone ⅡA reference solution and test solution respectively, and inject them under the chromatographic conditions of (1). Figure 4 and Figure 5 It can be seen that the main peak of the test sample has the same retention time as the reference sample. The results show that the excipients in the prepared freeze-dried preparation do not interfere with the determination of tanshinone ⅡA, and the method has good specificity.

[0102] (9) In vitro release experiment

[0103] Dialysis bag treatment: Cut the dialysis bag into small pieces of about 7 cm, and soak them in a 1000 mL beaker filled with purified water for 24 hours. Then heat the beaker on a digital constant temperature magnetic stirrer until it boils, and boil for 10 minutes or longer (be careful not to evaporate the water). After the solution in the beaker cools naturally, place the dialysis bag in 30% or 50% ethanol and store it in a refrigerator at 4°C (the dialysis bag must be kept immersed in the solution at all times). Gloves must be worn when using the dialysis bag to avoid introducing other impurities.

[0104] Release experiment of Tanshinone ⅡA and Tanshinone ⅡA nanostructured lipid carrier:

[0105] Accurately weigh 1 mg of tanshinone ⅡA and freeze-dried nanostructured lipid carrier containing 1 mg of tanshinone ⅡA and pour them into the treated dialysis bags respectively. Accurately measure 2 mL of purified water and add them to different dialysis bags respectively. Clamp the two ends with dialysis clamps and place them in a release cup containing 100 mL of 0.5% SDS saline solution. Place them in a constant temperature water bath shaking shaker (temperature is 37°C, speed is 100r / min). Sampling is performed at 0.0.5, 1, 2, 3, 4, 5, 6, 9, 12, 24, 48, and 72 hours, and the sampling volume is 2 mL each time. At the same time, the release medium of the same temperature and volume is added. Finally, the peak area and the concentration of the nanostructured lipid carrier of tanshinone ⅡA are determined by HPLC, and the cumulative release amount of the two is calculated. The cumulative release percentage is plotted against time. The release curve results are shown in Figure 6 and Figure 7 The results show that the release rate of the reference solution in the release medium of 0.5% SDS saline solution was faster in the first 24 hours, and then the release was slower. However, the release rate of the lyophilized powder of the nanostructured lipid carrier of Tanshinone ⅡA was slower, and the cumulative release percentage in 72 hours was less than 10%.

[0106] (10) Release curve mathematical equation fitting and release parameter calculation

[0107] The in vitro drug release behavior of tanshinone ⅡA nanostructured lipid carrier freeze-dried powder was fitted using zero-order, first-order kinetic models and Higuchi model, respectively, and the results are shown in Table 6. The results showed that the drug release behavior of tanshinone ⅡA nanostructured lipid carrier freeze-dried powder was more consistent with the first-order kinetic equation.

[0108] Table 6 Fitting results of cumulative drug release fraction of lyophilized powder of nanostructured lipid carrier of Tanshinone ⅡA

[0109] Model equation R Zero-order kinetic equation Q=0.63242t+4.86342 0.82127 First-order kinetic equation ln(1-Q)=-8.47051t+0.08476 0.97245 Higuchi Model <![CDATA[Q=1.14.68t 1 / 2+0.3493]]> 0.95171

[0110] from Figure 6 and Figure 7The in vitro release curve shows that the release of both the tanshinone ⅡA raw material and the nanostructured lipid carrier of tanshinone ⅡA is incomplete. The cumulative release of the raw material in 24 hours is only 25%, and the cumulative release of the nanostructured lipid carrier of tanshinone ⅡA in 72 hours is less than 10%. The main reason for the unsatisfactory cumulative release may be the selection of the release medium. Tanshinone ⅡA itself is a poorly soluble drug, and the release medium should continue to be examined and screened in later experiments. Nevertheless, compared with the nanostructured lipid carrier of tanshinone ⅡA, the original drug of tanshinone ⅡA has a cumulative release of about 25% in 24 hours, and the nanostructured lipid carrier of tanshinone ⅡA has a cumulative release of less than 8%, indicating that the nanostructured lipid carrier of tanshinone ⅡA has a significant sustained-release effect.

[0111] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. Other embodiments can be obtained based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.

Claims

1. A tanshinone ⅡA nanostructured lipid carrier, characterized in that: The preparation raw materials include tanshinone ⅡA, complex lipid, emulsifier and water; The complex lipids include solid lipids and liquid lipids.

2. The tanshinone ⅡA nanostructured lipid carrier according to claim 1, characterized in that: The solid lipids include one or more of polyethylene glycol 100 stearate, glyceryl monostearate, glyceryl behenate, glyceryl laurate, glyceryl myristicate and stearic acid; the liquid lipids include one or more of tricaprylin, liquid paraffin, castor oil, peppermint oil and oleic acid; The emulsifier includes one or more of Poloxamer 188, Tween 20, Tween 40, Tween 60, Tween 80, Span 20, Span 40, Span 60, Span 80, Bian Ze 35 and sodium lauryl sulfate.

3. The tanshinone ⅡA nanostructured lipid carrier according to claim 1 or 2, characterized in that: The mass ratio of the solid lipid to the liquid lipid is 1.25-2.0:1; The mass ratio of the composite lipid to the emulsifier is 2.4-3.6:0.05-0.3; The mass ratio of tanshinone ⅡA to the composite lipid is 0.01-0.02:1.2-3.6; The mass ratio of tanshinone ⅡA to water is 0.01-0.02:

50.

4. The tanshinone ⅡA nanostructured lipid carrier according to claim 3, characterized in that: The particle size of the tanshinone ⅡA nanostructured lipid carrier is less than 135 nm; The encapsulation rate of the tanshinone ⅡA nanostructured lipid carrier is above 85%.

5. The method for preparing the tanshinone ⅡA nanostructured lipid carrier according to any one of claims 1 to 4, characterized in that: The following steps are involved: The tanshinone ⅡA, the solid lipid and the liquid lipid are first heated and mixed to obtain an oil phase; The emulsifier and water are heated and mixed for a second time to obtain a water phase; After the oil phase and the water phase are mixed, emulsification and homogenization are performed in sequence to obtain the tanshinone ⅡA nanostructured lipid carrier.

6. The preparation method according to claim 5, characterized in that: The temperature of the first heating and mixing is 75-85°C; the temperature of the second heating and mixing is 65-80°C.

7. The preparation method according to claim 5, characterized in that: The emulsification time is 1 to 3 minutes, and the emulsification is carried out under stirring conditions, and the stirring speed is 5000 rpm.

8. The preparation method according to claim 5, characterized in that: The homogenization pressure is 800-1200 bar, and the homogenization times are 3-6 times.

9. A tanshinone ⅡA nanostructured lipid carrier freeze-dried powder, characterized in that: The tanshinone ⅡA nanostructured lipid carrier is obtained by freeze-drying the tanshinone ⅡA nanostructured lipid carrier described in any one of claims 1 to 4 or the tanshinone ⅡA nanostructured lipid carrier prepared by the preparation method described in any one of claims 5 to 9.

10. Use of the tanshinone ⅡA nanostructured lipid carrier described in any one of claims 1 to 4, the tanshinone ⅡA nanostructured lipid carrier prepared by the preparation method described in any one of claims 5 to 9, or the tanshinone ⅡA nanostructured lipid carrier lyophilized powder described in claim 9 in the preparation of anti-tumor drugs, anti-cardiovascular and cerebrovascular disease drugs or anti-inflammatory drugs.

Citation Information

Patent Citations

  • Psoralen-enveloped nanostructure lipid carrier preparation and preparation method thereof

    CN104013600A

  • Nanostructure lipid carrier containing schisandra chinensis lignans, preparation method and determination method thereof

    CN108309939A

  • Nano granules of solid lipid of tanshinone and its preparation method

    CN1480136A

  • Welding cover for pipe

    KR102037280B1